Imunon
Business Services · New Jersey, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
997 Lenox Dr Ste 100, Lawrenceville, New...Phone Number
(609) 896-9100Website
www.imunon.comRevenue
-Stock Symbol
IMNNIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Imunon
Imunon is a clinical-stage biotechnology company focused on developing innovative DNA-based immunotherapies and vaccines that work in harmony with the bodys immune system. The company leverages proprietary non-viral nucleic acid delivery platforms to create treatments for challenging cancers and infectious diseases, with a strong emphasis on harnessing natural biological mechanisms to generate durable therapeutic responses. Through its integrated research, development, and manufacturing capabilities, Imunon advances novel immunology-driven medicines designed to address unmet medical needs and improve patient outcomes across a broad range of serious health conditions.Explore more
Imunon Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Imunon your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Imunon is spiking on competitors!
Website visits: Recent activity has been detected on your website
Click to see if Imunon had a recent Job posting/layoffs
Imunon, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Imunon has new funding data
Earning: See what the market has to say on Imunon recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Imunon
Product Launch: Get notified when Imunon launches new products
Check if Imunon has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Imunon as Masked Content
Find 2 more new buyers
Compare Similar Companies to Imunon
Compare insights from companies similar to Imunon, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Imunon is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Imunon is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Imunon.
Imunon financials insights
Gather financial insights about Imunon, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2026
Stock/Share Issuance
$10M
Imunon Tech Stack
A closer look at the technologies used by Imunon
Most Recent Scoops
Earnings
Imunon has reported research and development expenses of $7.8 million for fiscal year 2025, a significant decrease compared to 2024, primarily due to the completion of the OVATION 2 study, optimization of the MRD study, and focused spending on OVATION 3 manufacturing and startup activities.
Earnings, Research & Development, Accounting, Financial Reporting, Finance
Project
Imunon has reported that multiple presentations at leading congresses in 2025 highlighted IMNN-001's profile of localized IL-12 delivery with negligible systemic exposure, favorable safety, and immune activation signals, with numerous investigators proactively seeking to join the Phase 3 OVATION 3 study.
Events, Medical Research, Pharmaceuticals, Clinical Operations
Project
Imunon has reported that data from its ongoing Phase 2 minimal residual disease (MRD) study, conducted in collaboration with Break Through Cancer, demonstrates preferential uptake of peritoneal macrophages, tumor microenvironment remodeling, complete pathological responses, and durable IL-12 and interferon gamma expression for IMNN-001, with excellent tolerability even in combination with bevacizumab.
Laboratory Operations, Medical Research, Pharmaceuticals, Clinical Operations
Earnings
Imunon has reported a net loss of $14.5 million, or $6.83 per share, for fiscal year 2025, compared to a net loss of $18.6 million, or $16.94 per share, in fiscal year 2024, reflecting improvement driven by cost discipline. Note: All share and per share amounts reflect the 15-for-1 reverse stock split effective July 2025 and the 15% stock dividend declared in Q3 2025.
Earnings, Accounting, Financial Reporting, Business Finance, Finance
Project
Laboratory Operations, Medical Research, Clinical Operations
Imunon News & Media
Imunon, Inc. (IMNN) Q1 2026 Earnings Call Transcript
Imunon, Inc. (IMNN) Q1 2026 Earnings Call May 12, 2026 11:00 AM EDTCompany ParticipantsStacy Lindborg - President, CEO & DirectorDouglas V.IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update
IMNN-001 is the First and Only frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancerIMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026
LAWRENCEVILLE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company will host a conference call at 11:00 a.m. EDT on Tuesday, May 12, 2026 to discuss financial results for the first quarter ended March 31, 2026 and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy including progress in advancing PhaseImunon, Inc. (IMNN) Q4 2025 Earnings Call Transcript
Imunon, Inc. (IMNN) Q4 2025 Earnings Call March 31, 2026 11:00 AM EDTCompany ParticipantsStacy Lindborg - President, CEO & DirectorDouglas V.
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Imunon
Sign Up For FreeTo access detailed company insights
Imunon is a clinical-stage biotechnology company focused on developing innovative DNA-based immunotherapies and vaccines that work in harmony with the bodys immune system. The company leverages proprietary non-viral nucleic acid delivery platforms to create treatments for challenging cancers and infectious diseases, with a strong emphasis on harnes... Read More
